[Basic research supporting discovery and lifecycle development of antibody therapeutics for hemophilia].

Authors

Kenichi Ogiwara

Published in

[Rinsho ketsueki] The Japanese journal of clinical hematology. Volume 67. Issue 9. Pages 1293-1303.

Abstract

Hemophilia treatment has shifted from conventional intravenous coagulation factor replacement toward reconstruction of hemostatic balance using non-factor agents. Antibody therapeutics have changed the drug discovery concept in hemophilia because of their long half-life, subcutaneous administration, target specificity, and flexibility of molecular engineering. Antibody-based therapeutics for hemophilia can be broadly divided into two categories: FVIIIa-mimetic bispecific antibodies, which bridge activated factor IX and factor X to substitute for the cofactor function of activated factor VIII, and anti-tissue factor pathway inhibitor antibodies, which rebalance hemostasis by attenuating the physiological anticoagulant pathway. This review summarizes basic research supporting discovery and lifecycle development of antibody therapeutics for hemophilia, focusing on molecular design, cell-based coagulation, rebalancing therapy, thrombin generation assay, laboratory implementation, concomitant hemostatic agents, anti-drug antibodies, and remaining challenges in individualized treatment.

PMID:
42951646
Bibliographic data and abstract were imported from PubMed on 29 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.